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[EBioMedicine 10 (2016) 299-305]Simon Fishel a, Deborah Baker b,⁎, Janine Elson a, Maha Ragunath c, Glenn Atkinson d, Adel Shaker e,
Ahmed Omar f, Rahnuma Kazem g, Ashley Beccles a, Ian A. Greer h
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b IHG Pharmaco Ltd, 20-22 Wenlock Road, London N1 7GU, UK
c CARE Nottingham, John Webster House, 6 Lawrence Drive, Nottingham NG8 6PZ, UK
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g CARE Northampton, Cliftonville, The Avenue, Northampton NN1 5BT, UK
h Faculty of Medical & Human Sciences Core Technology, Facility, 46 Grafton, Street, The University of Manchester, Manchester M13 9NT, UKThe authorswish to point out that there is an error in theAbstract (Findings paragraph) of this article,whereby the 47.7% formale ANXA5M2only
should have been 58.3%, as is in Table 5 and in Results section of the article.
The correct Findings paragraph of the Abstract should read as follows:
Findings
The tested and treated cohort of ANXA5M2 carriers achieved a similar live birth rate (37.9%) per ET cycle compared to both themore fertile com-
parison group (38.5%), and to the 103 matched controls (33.0%). Signiﬁcantly more treated male carrier only couples had a live birth versus female
M2 only (58.3% vs. 25.0% p = 0.045).DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.06.024.
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